United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Pfizer Inc said on Wednesday that final results from the late-stage trial of its COVID-19 vaccine show it was 95% effective, adding it had the required two-months of safety data and would apply for emergency U.S. authorization within days.

Pfizer ends COVID-19 trial with 95% efficacy, to seek emergency-use authorization

Pfizer Inc said on Wednesday that final results from the late-stage trial of its COVID-19 vaccine showed it was 95% effective, adding it had the required two-months of safety data and would apply for emergency U.S. authorization within days.

Instant View: Pfizer ends COVID-19 trial with 95% efficacy

It comes after Moderna announced interim data from Phase 3 trials showed its vaccine candidate to be 94.5% effective.

Pfizer-BioNTech Says Covid-19 Vaccine Is 95% Effective, Will Seek Emergency Approval Within Days

Drugmaker Pfizer has provided updated analysis around its COVID-19 vaccine Phase 3 clinical trial data, saying that in the final result of its analysis of the 44,000-participant trial, its COVID-19 vaccine candidate proved 95% percent effective. This is a better efficacy rate than Pfizer reported previously, when it announced a 90% effectiveness metric based on […]

Pfizer says its COVID-19 vaccine is 95% effective in final clinical trial results analysis

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the study's primary efficacy endpoints. Analysis of the data indicates a vaccine efficacy rate of 95% (p

Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints

Dr. Leo Nissola shares what investors need to know about the latest developments in the mRNA vaccine space.

The Motley Fool Sits Down With A Doctor About Pfizer's Coronavirus Vaccine News

Pfizer and BioNTech said final analysis found coronavirus vaccine was 95% effective in preventing Covid-19 and appeared to fend off severe disease.

Pfizer says final data analysis shows Covid vaccine is 95% effective – plans to submit to FDA in 'days'

On November 9, the world learned that Pfizer's coronavirus vaccine is highly effective.  Even though details were sparse in that release, the news that the vaccine was highly protective against COVID-19 showed a potential exit path from this pandemic. 

Pfizer says its coronavirus vaccine is 95% effective as it gears up to ask the FDA to authorize the shot

Pfizer Inc. Chief Executive Albert Bourla said the company and its partner BioNTech SE have passed the minimum two-month follow-up that the U.S. Food and Drug Administration requires as a safety milestone to obtain emergency use authorization for its COVID-19 vaccine candidate, according to media reports. Bourla made the comment at New York Times and STAT summits on Tuesday.

Pfizer CEO says COVID-19 vaccine candidate has passed FDA safety milestone

AbbVie

Bristol-Myers

Merck

The Oracle of Omaha and his investing lieutenants knew what they were doing in buying AbbVie, BMS, Merck, and Pfizer.

Here's Exactly Why Warren Buffett Loaded Up on Big Pharma Stocks

The Pfizer-BioNTech vaccine has now proved 95% effective in preventing coronavirus and has met the safety criteria needed for emergency authorisation, the firms have said.

Pfizer vaccine 95% effective and will be submitted for authorisation 'within days'

The drugmaker is at the vanguard of the global battle against COVID-19.

Pfizer May File for Emergency Authorization of Coronavirus Vaccine Within the Week

Pfizer, Inc. (NYSE: PFE) shares, which came under selling pressure Monday in response to positive news on a rival vaccine candidate from Moderna, Inc. (NASDAQ: MRNA), were rebounding Tuesday after Pfizer unveiled an action plan to distribute its COVID-19 vaccine candidate upon successful regulatory clearance. What Happened: Pfizer announced the U.S. COVID-19 Immunization Pilot Program, which will facilitate delivery and deployment of BNT162b2, the investigational vaccine it is co-developing with German biopharma BioNTech SE – ADR (NASDAQ: BNTX).

Pfizer's Pilot Program For Vaccine Distribution In 4 States: What You Should Know

The company has selected Texas, New Mexico, Tennessee, and Rhode Island for the pilot program

Pfizer Inc. initiates Covid-19 vaccine shipment trial

Berkshire Hathaway bought $5.7bn worth of shares in four companies in third quarter

Warren Buffett makes big investment in US pharmaceutical firms

The company hopes to preemptively tackle any distribution problems caused by the ultra-cold storage requirements of the vaccine.

Pfizer To Test Covid-19 Vaccine Delivery Program In Four States

NEW YORK--(BUSINESS WIRE)-- #PFE--Scott+Scott Attorneys at Law LLP Investigates Pfizer, Inc.'s (PFE) Directors and Officers for Breach of Fiduciary Duties

Scott+Scott Attorneys at Law LLP Investigates Pfizer, Inc.'s (PFE) Directors and Officers for Breach of Fiduciary Duties

Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway (NYSE:BRK.A) (NYSE:BRK.B) filed its 13F report for the third quarter on Monday this week. The announcement revealed that the Oracle of Omaha made some exciting changes to his portfolio during the reported period, including several investments in pharmaceutical companies.

Has Buffett Become an Expert on Big Pharma?

Moderna

Just as the novel coronavirus was gaining a foothold in the United States in mid-March, Pfizer Inc Chief Executive Albert Bourla called on his top vaccine scientists and laid out a clear mission:

How two companies sprinted ahead in extraordinary race for a COVID vaccine

Moderna's (MRNA) coronavirus vaccine candidate seems to be more effective and its logistics less onerous than Pfizer and BioNTech's candidate.

Moderna's (MRNA) Coronavirus Vaccine Progress Hurts Pfizer

The four states involved won't be getting COVID-19 vaccine doses early. They will be helping develop systems to ensure that the vaccine is distributed efficiently.

Pfizer Launching Coronavirus Immunization Pilot Program in the U.S.

Johnson & Johnson

Regeneron Pharmaceuticals

Sanofi

SPDR S&P Pharmaceuticals ETF

Zoetis

Pharmaceutical stocks help make the world go round. Without them, common ailments would plague our lives.

7 Pharmaceutical Stocks to Buy for 2021 and Beyond 

Pfizer (PFE) and BioNTech's (BNTX) stocks decline after Moderna COVID-19 vaccine candidate proves 94.5% effective and can be stored at standard refrigerator temperature.

Pfizer (PFE), BioNTech Fall After Moderna COVID-19 Vaccine Data

Better Coronavirus Vaccine: Moderna's mRNA-1273 or Pfizer and BioNTech's BNT162b2?

Coronavirus vaccine race is now at its peak following Moderna's (MRNA) 94.5% effective vaccine in Phase 3 trials. Pfizer (PFE) also bragged about the effectiveness of its vaccine to be more than 90%.

News for Pfizer Stock (PFE)